• By Kevin E. Noonan —

    FiercePharmaFiercePharma today reported sales rankings for the top 15 pharmaceutical companies in 2018, in comparison to 2017 sales.  As reported today, "the top 15 names are the same against prior year rankings, but the order has shifted."  2018 sales were up for all reported companies except Gilead, AstraZeneca, and Teva, and the change in rankings generally had more to do with competitors' improvements (and increased sales) than reductions in sales 2018 to 2017.  Increases were notable for Bristol Myers-Squibb and Takeda, while Sanofi and Gilead showed reduced sales.  And the report notes that Boehringer Ingelheim’s exclusion from the data was the result of (relatively) late sales reporting (due April 17th).

    As reported, "[f]or these rankings and company profiles, FiercePharma consulted company earnings reports, securities filings, earnings transcripts and analyst reports, plus our own archives," while segregating Bayer's plant science unit as being too far removed from human or animal health."

    In addition, the report notes that the industry set a record with 59 novel drugs being approved in 2018.  But also included in the report are challenges expected in the industry, including the departure of Scott Gottlieb as head of FDA and calls by politicians on both sides of the aisle, and the Trump administration, for lower drug prices.

    The top 15 pharma companies by 2018 revenue:

    1. Johnson & Johnson
    2. Roche
    3. Pfizer
    4. Novartis
    5. Merck & Co.
    6. GlaxoSmithKline
    7. Sanofi
    8. AbbVie
    9. Bayer
    10. Eli Lilly
    11. Amgen
    12. Bristol-Myers Squibb
    13. Gilead Sciences
    14. AstraZeneca
    15. Teva Pharmaceutical Industries
  • By Donald Zuhn —

    Federal Circuit SealLast week, in Cleveland Clinic Foundation v. True Health Diagnostics LLC, the Federal Circuit affirmed a decision by the U.S. District Court for the Eastern District of Virginia holding claim 1 of U.S. Patent No. 9,575,065 and claims 1 and 2 of U.S. Patent No. 9,581,597 invalid under 35 U.S.C. § 101 as directed to an ineligible natural law.  Finding the asserted claims to be patent ineligible, the District Court had dismissed a complaint for patent infringement filed by Cleveland Clinic Foundation and Cleveland HeartLab, Inc. ("Cleveland Clinic") against True Health Diagnostics LLC under Rule 12(b)(6) (see "Cleveland Clinic Foundation v. True Health Diagnostics, LLC (E.D. Va. 2017)").  In affirming the District Court, the Federal Circuit determined that its precedent, and not the U.S. Patent and Trademark Office's guidance, must control.

    The '065 and '597 patents disclose "diagnostic test[s] which can be used to determine whether an individual . . . is at a lower risk or higher risk of developing or having cardiovascular disease," which are "based on the discovery that patients with coronary artery disease (CAD) have significantly greater levels of leukocyte and blood myeloperoxidase (MPO) levels" ('065 patent, col. 1, ll. 21–25, and col. 2, ll. 36-39).  The sole claim of the '065 patent recites:

    1.  A method of detecting elevated MPO mass in a patient sample comprising:
        a)  obtaining a plasma sample from a human patient having atherosclerotic cardiovascular disease (CVD); and
        b)  detecting elevated MPO mass in said plasma sample, as compared to a control MPO mass level from the general population or apparently healthy subjects, by contacting said plasma sample with anti-MPO antibodies and detecting binding between MPO in said plasma sample and said anti-MPO antibodies.

    The only two claims of the '597 patent recite:

    1.  A method for identifying an elevated myeloperoxidase (MPO) concentration in a plasma sample from a human subject with atherosclerotic cardiovascular disease comprising:
        a)  contacting a sample with an anti-MPO antibody, wherein said sample is a plasma sample from a human subject having atherosclerotic cardiovascular disease;
        b)  spectrophotometrically detecting MPO levels in said plasma sample;
        c)  comparing said MPO levels in said plasma sample to a standard curve generated with known amounts of MPO to determine the MPO concentration in said sample; and
        d)  comparing said MPO concentration in said plasma sample from said human subject to a control MPO concentration from apparently healthy human subjects, and identifying said MPO concentration in said plasma sample from said human subject as being elevated compared to said control MPO concentration.

    2.  The method of claim 1, further comprising, prior to step a), centrifuging an anti-coagulated blood sample from said human subject to generate said plasma sample.

    The opinion notes that the Federal Circuit had previously addressed the subject matter eligibility of a parent patent, U.S. Patent No. 7,223,552, in Cleveland Clinic Foundation v. True Health Diagnostics, LLC, 859 F.3d 1352 (Fed. Cir. 2017) ("Cleveland Clinic I"), in which the Court affirmed a motion to dismiss granted by the District Court for the Northern District of Ohio, which in turn found the asserted claims of four Cleveland Clinic patents, including the '552 patent, as being directed to patent-ineligible subject matter.  Claim 11 of the '552 patent, which the opinion notes is exemplary, recites:

    11.  A method of assessing a test subject's risk of having atherosclerotic cardiovascular disease, comprising
        comparing levels of myeloperoxidase in a bodily sample from the test subject with levels of myeloperoxidase in comparable bodily samples from control subjects diagnosed as not having the disease, said bodily sample being blood, serum, plasma, blood leukocytes selected from the group consisting of neutrophils, monocytes, sub-populations of neutrophils, and sub-populations of monocytes, or any combination thereo[f];
        wherein the levels of myeloperoxidase in the bodily [samples] from the test subject relative to the levels of [m]yeloperoxidase in the comparable bodily samples from control subjects is indicative of the extent of the test subject's risk of having atherosclerotic cardiovascular disease.

    The opinion also notes that In Cleveland Clinic I, the Court held the methods of the '552 patent invalid under § 101 as being "directed to the ineligible natural law that blood MPO levels correlate with atherosclerotic CVD," and also held that "because the patent did not purport to have invented any of the biological techniques used to detect MPO or the statistical methods used to compare a patient's MPO levels to the control group, the claims recited no further inventive concept sufficient to transform the nature of the claims into a patent-eligible application of the natural law."  According to the opinion, the asserted claims of the '065 and '597 patents recite methods of identifying and detecting MPO, in contrast to the method of assessing atherosclerotic CVD risk from blood MPO levels in the '552 patent.

    On appeal, Cleveland Clinic argued that the claims are not directed to a natural law, but to the technique of using an immunoassay to measure the blood MPO levels of patients with atherosclerotic CVD, that the correlation between blood MPO levels and atherosclerotic CVD is not a natural law because it can only be detected using certain techniques (since prior art techniques were too invasive or failed to predict CVD risk), and that using an immunoassay to detect the correlation between blood MPO levels and atherosclerotic CVD supplies an inventive concept sufficient to transform the claims into patent-eligible subject matter.  True Health countered by arguing that the correlation between atherosclerotic CVD and blood MPO levels is a natural law because it exists in nature apart from human intervention and that using known techniques in a standard way to observe a natural law neither renders the claims directed to something other than the natural law nor supplies an additional inventive concept.

    The Federal Circuit agreed with True Health, concluding as the Court did in Cleveland Clinic I that the claims are directed to the natural law that blood MPO levels correlate with atherosclerotic CVD.  In response to Cleveland Clinic's argument that the claims of the '552 patent, which were previously found to be invalid as patent-ineligible, could be distinguished from the claims of the '065 and '597 patents because the former are directed to methods of "assessing a test subject's risk of having atherosclerotic [CVD]" by comparing the subject's MPO levels to a control group, and the latter are directed to "techniques for detecting elevated levels of MPO in the blood of patients having CVD," the Federal Circuit found this distinction (quoting the District Court) to be "overly superficial."  The opinion explains that the asserted claims:

    [A]re not directed to new techniques for performing an immunoassay to detect a patient's blood MPO levels.  They only recite applying known methods to detect MPO levels in plasma, comparing them to standard MPO levels, and reaching a conclusion:  that the patient's blood MPO levels are elevated in comparison to a control group.  This conclusion is simply another articulation of the natural law that blood MPO levels correlate with atherosclerotic CVD.  Thus, as we held in Cleveland Clinic I, the claims are directed to the patent-ineligible natural law that blood MPO levels correlate with risk of atherosclerotic CVD.

    The Federal Circuit also disagreed with Cleveland Clinic's argument that the correlation of blood MPO levels with atherosclerotic CVD is not a natural law because blood MPO levels can only be observed using certain techniques, stating that "[i]nadequate measures of detection do not render a natural law any less natural."  The Court also found Cleveland Clinic's argument that the inventive concept was supplied by using an immunoassay to detect the correlation between blood MPO levels and atherosclerotic CVD to be unpersuasive, stating that the argument that "using a known technique in a standard way to observe a natural law can confer an inventive concept—has been consistently rejected by this court in circumstances nearly identical to this case" (citing Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, 915 F.3d 743, 747 (Fed. Cir. 2019), and Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015)).

    On appeal, Cleveland Clinic also argued that the District Court failed to give the appropriate deference to the subject matter eligibility guidance published by the U.S. Patent and Trademark Office, as required by Skidmore v. Swift & Co., 323 U.S. 134 (1944), and also erred by not granting Skidmore deference to the Examiner's decision to allow the '065 and '597 patent applications in light that guidance.  As was noted by the District Court in its opinion, during prosecution of the application that issued as the '065 patent, the Examiner initially rejected the claims under 35 U.S.C. § 101 as being directed to an unpatentable abstract idea.  Cleveland Clinic overcame that rejection by citing Example 29 of the U.S. Patent and Trademark Office's "May 2016 Subject Matter Eligibility Update" (see "Subject Matter Eligibility Guidance — Example on Diagnosing and Treating Julitis").  Example 29 sets forth seven claims directed to the detection of a hypothetical protein, JUL-1, and the diagnosis and/or treatment of a hypothetical autoimmune disease, julitis.  The first two claims of Example 29 recite:

    1.  A method of detecting JUL-1 in a patient, said method comprising:
        a.  obtaining a plasma sample from a human patient; and
        b.  detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with an anti-JUL-1 antibody and detecting binding between JUL-1 and the antibody.

    2.  A method of diagnosing julitis in a patient, said method comprising:
        a.  obtaining a plasma sample from a human patient;
        b.  detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with an anti-JUL-1 antibody and detecting binding between JUL-1 and the antibody; and
        c.  diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected.

    According to Example 29, claim 1 is considered to be patent eligible and claim 2 is considered to be patent ineligible.  The Example explains that claim 1 is eligible because steps (a) and (b) of the claim "do not recite or describe any recognized exception."  As a result, the analysis of this claim ends with Step 2A of analytic framework set forth in the Interim Guidance (i.e., determining whether the claim is directed to a judicial exception), and the Example notes that there is no need to proceed with Step 2B of the analytic framework (i.e., determining whether any element, or combination of elements, in the claim is sufficient to ensure that the claim amounts to significantly more than the judicial exception).

    In overcoming the § 101 rejection, Cleveland Clinic argued that the rejected claims more closely resembled claim 1 of Example 29 as opposed to exemplary claim 2 because the rejected claims were directed to a method of detecting myeloperoxidase rather than a method of diagnosing atherosclerotic cardiovascular disease.  The Examiner withdrew the rejection and the '065 patent proceeded to issuance.  As for the '597 patent, which was similarly rejected under § 101 as being directed to patent ineligible subject matter, Cleveland Clinic overcame the rejection by citing Example 29 and arguing that the claims amount to significantly more than the judicial exception.

    On appeal, True Health countered that the USPTO guidance is neither persuasive nor relevant to the eligibility of the asserted claims, and that the District Court correctly found that claim 1 of Example 29 of the USPTO guidance is directed to a method of detecting a protein in a plasma sample without linking the results to a disease or other natural phenomenon.

    With respect to Cleveland Clinic's argument that the District Court failed to give the appropriate deference to the USPTO's guidance, the Federal Circuit agreed with True Health that the District Court did not err in finding the asserted claims ineligible, stating that:

    While we greatly respect the PTO's expertise on all matters relating to patentability, including patent eligibility, we are not bound by its guidance.  And, especially regarding the issue of patent eligibility and the efforts of the courts to determine the distinction between claims directed to natural laws and those directed to patent-eligible applications of those laws, we are mindful of the need for consistent application of our case law.

    The Court also noted that claim 1 of Example 29 of the guidance "is strikingly similar to claim 1 of U.S. Patent 6,258,540 at issue in Ariosa."  Claim 1 of the '540 patent recites:

    1.  A method for detecting a paternally inherited nucleic acid of fetal origin performed on a maternal serum or plasma sample from a pregnant female, which method comprises
        amplifying a paternally inherited nucleic acid from the serum or plasma sample and
        detecting the presence of a paternally inherited nucleic acid of fetal origin in the sample.

    Thus, the Court declared that:

    We have considered Example 29 and the arguments relating to it, but to the extent that Example 29–Claim 1 is analogous to the claims at issue, Ariosa must control.  Accordingly, we decline to follow the PTO's Example 29–Claim 1 and conclude that the district court did not err in its consideration of the PTO's subject matter eligibility guidance.

    Thus, the Court determined that the District Court correctly concluded that the asserted claims are directed to a natural law and recite no other inventive concept, and therefore affirmed the District Court's decision finding the claims to be patent ineligible and dismissing Cleveland Clinic's complaint.

    Cleveland Clinic Foundation v. True Health Diagnostics LLC (Fed. Cir. 2019)
    Nonprecedential disposition
    Panel:  Circuit Judges Lourie, Moore, and Wallach
    Opinion by Circuit Judge Lourie

  • CalendarApril 9, 2019 – Patent Quality Chat on "New pilot program for motions to amend in AIA trial proceedings" (U.S. Patent and Trademark Office) – 12:00 to 1:00 pm (ET)

    April 9, 2019 – "Protecting Software as a Medical Device: Patents, Design Patents and Trade Secrets" (Strafford) – 1:00 to 2:30 pm (EDT)

    April 16, 2019 – "Trade Secrets Litigation 2019: Developments from the Trial Courts to the Supreme Court" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    April 18, 2019 – "Antibody Patenting: U.S. and Asian Perspectives" (Strafford) – 1:00 to 2:30 pm (EDT)

    April 29-30, 2019 – Paragraph IV Disputes master symposium (American Conference Institute) – New York, NY

    April 23, 2019 – "Recent Developments in Biopharma Patent Law" (McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs) – 9:30 am to 1:30 pm, San Diego, CA (Hyatt Regency La Jolla at Aventine)

    April 24, 2019 – "Recent Developments in Biopharma Patent Law" (McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs) – 9:30 am to 1:30 pm, Burlingame, CA (Hyatt Regency San Francisco Airport)

    May 16-17, 2019 – Advanced Summit on Life Sciences Patents (American Conference Institute) – New York, NY

  • MBHB Logo 2McDonnell Boehnen Hulbert & Berghoff LLP will be offering a live webinar entitled "Trade Secrets Litigation 2019: Developments from the Trial Courts to the Supreme Court" on April 16, 2019 from 10:00 am to 11:15 am (CT).  In this presentation, MBHB attorney and Patent Docs contributor Joshua Rich will address the following topics:

    • The consideration requirement to support restrictive covenant cases in various courts, both Federal and State
    • Ex parte seizure developments under the DTSA
    • Pleading pitfalls in DTSA cases
    • The Supreme Court's consideration of the trade secrets exception to FOIA in Food Marketing Institute v. Argus Leader Media

    While there is no fee to participate, attendees must register in advance.  Those wishing to register can do so here.  CLE credit is pending for the states of California, Illinois, New Jersey, New York, North Carolina, and Virginia.

  • MBHB Logo 2McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs will be hosting two onsite CLE programs on "Recent Developments in Biopharma Patent Law" from 9:30 am to 1:30 pm (PT) on April 23, 2019 in San Diego, CA and on April 24, 2019 in Burlingame, CA.  MBHB attorneys and Patent Docs authors Kevin Noonan and Donald Zuhn, and MBHB attorneys Josh Rich, Lisa Hillman, Sarah Fendrick, John Conour, Nate Chongsiriwatana, and Nicole Grimm will provide presentations on the following topics:

    • Updates on Subject Matter Eligibility Analysis
    • Patenting Repurposed Drugs
    • Antibody Patenting after Amgen v. Sanofi
    •
    The State of Biotech Patenting: Challenges
    • Maximizing Patent Term for Products Subject to Regulatory Review
    • Impact of Secondary Patents on Market Exclusivity
    • Considerations for Biotech Cannabis Patents
    • Strategies for Post-Grant Proceedings for Generics and Biosimilars

    There is no registration fee for the program.  However, because space is limited, those interested in attending the program must register by contacting Susan Hall at hall@mbhb.com.  When registering, please note at which location you plan to attend:  San Diego (Hyatt Regency La Jolla at Aventine) or Burlingame (Hyatt Regency San Francisco Airport).

  • USPTO SealThe U.S. Patent and Trademark Office will be offering the next webinar in its Patent Quality Chat webinar series from 12:00 to 1:00 pm (ET) on April 9, 2019.  In the latest webinar, on the "New pilot program for motions to amend in AIA trial proceedings," Deputy Chief Judge Jackie Bonilla and Lead Judge Jessica Kaiser from the USPTO's Patent Trial and Appeal Board (PTAB) will discuss how the new pilot program will provide opportunities not only to receive feedback from the PTAB about a first motion to amend, but also to file a second motion to amend based on that feedback.

    Additional information regarding this webinar, including instructions for viewing the webinar, can be found here.

  • Strafford #1Strafford will be offering a webinar entitled "Antibody Patenting: U.S. and Asian Perspectives" on April 18, 2019 from 1:00 to 2:30 pm (EDT).  Jeffrey M. Jacobstein and Murphy, Amanda of Finnegan Henderson Farabow Garrett & Dunner, Osamu Yamamoto of Yuasa and Hara, and Daniel Miao Cheng of Cheng & Peng will guide patent counsel on the patentability requirements at the USPTO, JPO and CNIPA/CPO when claiming antibodies, recent case law that could impact those claims, and how to protect antibody inventions in light of the latest developments.  The webinar will review the following issues:

    • How broadly can the applicant claim?
    • How much support is needed on a filing?
    • What are the differences between U.S. requirements, JPO requirements and CNIPA/CPO requirements?
    • What is a sufficient description of a genus?
    • Can functional language be included?
    • When can post-filing data be used?
    • What is needed to demonstrate the nonobviousness of antibody claims in the different jurisdictions?

    The registration fee for the webcast is $347.  Those interested in registering for the webinar, can do so here.

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Disqualification: Lessons from Recent Cases" on April 10, 2019 from 2:00 to 3:00 pm (ET).  William Freivogel, Martin Kaminsky of Greenberg Traurig LLP, and Deanna Kwong of Hewlett Packard Enterprise will look at professional responsibility decisions, as well as the approaches taken by courts when considering disqualification of counsel and discuss whether court disqualification will generally occur solely because of an ethical violation — or whether the totality of the circumstances will be analyzed.  The panel will analyze recent cases with conflicts issues, including those relating to:

    • Corporate affiliations
    • Advance conflict waivers
    • Marketing conversations with prospective clients
    • Lateral hires
    • The hot potato doctrine

    The registration fee for the webinar is $135 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Protecting Software as a Medical Device: Patents, Design Patents and Trade Secrets" on April 9, 2019 from 1:00 to 2:30 pm (EDT).  Cory C. Bell, Elizabeth D. Ferrill, and Susan Y. Tull of Finnegan Henderson Farabow Garrett & Dunner will guide counsel for companies in the medical device industry on protecting software as a medical device (SaMD) and discuss the FDA rules regulating SaMD and how to leverage IP law to protect SaMD.  The webinar will review the following issues:

    • What are the hurdles for patent counsel to demonstrate a software-related claim is not abstract?
    • What factors should counsel consider when determining what type of IP protection to seek?
    • What guidance have the courts provided in recent decisions concerning patent eligibility for software-related inventions?

    The registration fee for the webcast is $347.  Those interested in registering for the webinar, can do so here.

  • By Donald Zuhn –-

    USPTO Implements New System for Ordering Certified Copies of Documents

    USPTO SealIn a notice posted on the U.S. Patent and Trademark Office website last month, the Office announced that it was implementing the Certified Copy Center (CCC) Storefront, a new web system for ordering certified copies of patent and trademark documents.  The new system will replace the current Order Entry Management System (OEMS), which can be accessed through the Private Patent Information and Retrieval (PAIR) system.  The new system will be accessed via a user's MyUSPTO page.  According to the Office's notice, a beta version of the CCC Storefront was issued last month, and the full production release of the CCC Storefront is scheduled for later this month.


    USPTO Announces Expansion of Phase 1 of Access to Relevant Prior Art Initiative

    Access to Relevant Prior ArtIn a Patent Alert e-mail distributed earlier this year, the U.S. Patent and Trademark Office announced an update to Phase 1 of the Office's Access to Relevant Prior Art Initiative, which began on November 1, 2018.  The Access to Relevant Prior Art (RPA) Initiative is an effort by the Office to increase patent examination quality and efficiency through the development of an automated tool for USPTO examiners, which will import relevant prior art and other pertinent information from sources such as related U.S. applications, counterpart foreign applications, and International (PCT) applications into pending U.S. patent applications as early as possible in prosecution.  The Office envisions the RPA initiative as a way "to potentially reduce the burden on applicants with complying with the duty of disclosure."

    In Phase 1 of the RPA initiative, information in the form of citations on PTO/SB/08 and PTO-892 forms from the immediate parent application will be imported into the continuing application for consideration by the Examiner.  The Office noted last year that Phase 1 would be limited to select art units — in particular, Art Unit 2131 in Technology Center 2100, with a wider release to Art Units 1616, 1731, 2431, 2675, 2879, 2922, 3635, and 3753 this year.  The Office has now expanded the RPA Initiative to include those additional art units.  Applicants will receive a Notice of Imported Citations from the Office informing the applicant that an application has been included in the Initiative and listing the citations from the immediate parent application that have been imported into the application.

    Additional information regarding the RPA initiative can be found at the Office's Access to Relevant Prior Art Initiative webpage.


    ATCC Changes Deposit Requirements for Seeds

    ATCCIn a notice posted on the U.S. Patent and Trademark Office website on March 1, the Office informed stakeholders of a change being implemented by the American Type Culture Collection (ATCC) with regard to the deposit of plant seeds.  The Office notes that in order to ensure compliance with 35 U.S.C. § 112 for utility plant inventions (as opposed to patent applications submitted under the Plant Patent Act, 35 U.S.C. §§ 161-164), the deposit of inventive seeds may supplement the disclosure in the specification to provide an adequate written description of the invention and to enable those skilled in the art to make and use the claimed invention.  The Office also notes that a deposit must comply with the biological deposit rules (37 C.F.R. §§ 1.801-1.809) to be relied upon to meet the requirements of 35 U.S.C. § 112.  For plant seeds, biological deposit rules require that deposits be made with one of seven Budapest Treaty International Depositary Authorities (IDAs), of which the ATCC is one of the largest.

    For seed deposits, the ATCC previously required depositors to deposit 2,500 seeds (consisting of 25 packages of 100 seeds each).  Because an analysis of past deposits indicated that at most, only four seed packages had been requested for any one deposit, the ATCC has reduced the number of seeds that must be deposited to 625 (i.e., 25 packages of 25 seeds), with the change taking effect on January 1, 2019.

    As a result of the ATCC change, the Office has indicated that MPEP § 2403.02 will be revised to indicate that as long as the number of seeds deposited complies with the requirements of the IDA where the deposit is made, the USPTO will consider such submission as satisfying the rules under 37 C.F.R. §§ 1.801-1.809.